Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN ... Business Wire (press release) The company will also present results from the investigational trials of its late-stage MS pipeline, including TECFIDERA™ (dimethyl fumarate), peginterferon beta-1a and daclizumab high-yield process (DAC HYP). As part of the company's overall ... |
